189 related articles for article (PubMed ID: 7729895)
41. DNA vaccines against chronic lung infections by Pseudomonas aeruginosa.
Staczek J; Gilleland LB; van der Heyde HC; Gilleland HE
FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):147-53. PubMed ID: 12832118
[TBL] [Abstract][Full Text] [Related]
42. [Obtaining of outer membrane protein I of Pseudomonas aeruginosa and assessment of its antigenic properties].
Gatypova EV; Zlygostev SA; Kaloshin AA; Mikhaĭlova NA
Zh Mikrobiol Epidemiol Immunobiol; 2008; (6):50-3. PubMed ID: 19189463
[TBL] [Abstract][Full Text] [Related]
43. [Study of immunogenic properties of recombinant outer membrane proteins F and L from Pseudomonas aeruginosa].
Kaloshin AA; Zlygostev SA; Gatypova EV; Mikhaĭlova NA
Zh Mikrobiol Epidemiol Immunobiol; 2008; (5):76-9. PubMed ID: 19004286
[TBL] [Abstract][Full Text] [Related]
44. OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa.
Ding B; von Specht BU; Li Y
Vaccine; 2010 Jun; 28(25):4119-22. PubMed ID: 20433804
[TBL] [Abstract][Full Text] [Related]
45. Immunological evaluation of OMP-F of native Iranian Pseudomonas aeruginosa as a protective vaccine.
Ahmadi H; Tabaraie B; Maleknia S; Pormirzagholi F; Nejati M; Hedayati MH
J Infect Dev Ctries; 2012 Oct; 6(10):721-6. PubMed ID: 23103894
[TBL] [Abstract][Full Text] [Related]
46. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
Zaidi TS; Priebe GP; Pier GB
Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
[TBL] [Abstract][Full Text] [Related]
47. Protective efficacy of recombinant exotoxin A--flagellin fusion protein against Pseudomonas aeruginosa infection.
Farajnia S; Peerayeh SN; Tanomand A; Majidi J; Goudarzi G; Naghili B; Rahbarnia L
Can J Microbiol; 2015 Jan; 61(1):60-4. PubMed ID: 25496361
[TBL] [Abstract][Full Text] [Related]
48. Multicomponent Pseudomonas aeruginosa Vaccines Eliciting Th17 Cells and Functional Antibody Responses Confer Enhanced Protection against Experimental Acute Pneumonia in Mice.
Shaikh MOF; Schaefers MM; Merakou C; DiBlasi M; Bonney S; Liao T; Zurakowski D; Kehl M; Tabor DE; DiGiandomenico A; Priebe GP
Infect Immun; 2022 Oct; 90(10):e0020322. PubMed ID: 36069593
[TBL] [Abstract][Full Text] [Related]
49. Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus.
Brennan FR; Jones TD; Gilleland LB; Bellaby T; Xu F; North PC; Thompson A; Staczek J; Lin T; Johnson JE; Hamilton WDO; Gilleland HE
Microbiology (Reading); 1999 Jan; 145 ( Pt 1)():211-220. PubMed ID: 10206701
[TBL] [Abstract][Full Text] [Related]
50. [Immunobiological properties of recombinant L peptide from the Pseudomonas aeruginosa outer membrane].
Gatypova EV; Zlygostev SA; Kaloshin AA; Mikhaĭlova NA
Vestn Ross Akad Med Nauk; 2009; (4):25-8. PubMed ID: 19514308
[TBL] [Abstract][Full Text] [Related]
51. Pseudomonas aeruginosa outer membrane lipoprotein I gene: molecular cloning, sequence, and expression in Escherichia coli.
Duchêne M; Barron C; Schweizer A; von Specht BU; Domdey H
J Bacteriol; 1989 Aug; 171(8):4130-7. PubMed ID: 2502533
[TBL] [Abstract][Full Text] [Related]
52. Potential of protein OprF of Pseudomonas in bivalent vaccines.
Hancock RE; Wong R
Behring Inst Mitt; 1997 Feb; (98):283-90. PubMed ID: 9382752
[TBL] [Abstract][Full Text] [Related]
53. Recombinant outer membrane protein F-B subunit of LT protein as a prophylactic measure against Pseudomonas aeruginosa burn infection in mice.
Farsani HH; Rasooli I; Gargari SL; Nazarian S; Astaneh SD
World J Methodol; 2015 Dec; 5(4):230-7. PubMed ID: 26713284
[TBL] [Abstract][Full Text] [Related]
54. A chimeric influenza virus expressing an epitope of outer membrane protein F of Pseudomonas aeruginosa affords protection against challenge with P. aeruginosa in a murine model of chronic pulmonary infection.
Staczek J; Gilleland HE; Gilleland LB; Harty RN; García-Sastre A; Engelhardt OG; Palese P
Infect Immun; 1998 Aug; 66(8):3990-4. PubMed ID: 9673294
[TBL] [Abstract][Full Text] [Related]
55. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy.
Lee NG; Jung SB; Ahn BY; Kim YH; Kim JJ; Kim DK; Kim IS; Yoon SM; Nam SW; Kim HS; Park WJ
Vaccine; 2000 Mar; 18(18):1952-61. PubMed ID: 10699346
[TBL] [Abstract][Full Text] [Related]
56. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
[TBL] [Abstract][Full Text] [Related]
57. Construction of a Protective Vaccine Against Lipopolysaccharide-Heterologous
Liu C; Pan X; Xia B; Chen F; Jin Y; Bai F; Priebe G; Cheng Z; Jin S; Wu W
Front Immunol; 2018; 9():1737. PubMed ID: 30093906
[No Abstract] [Full Text] [Related]
58. Post-exposure immunization by capsid-modified AdC7 vector expressing Pseudomonas aeruginosa OprF clears P. aeruginosa respiratory infection.
Gomi R; Sharma A; Wu W; Sung B; Worgall S
Vaccine; 2017 Dec; 35(51):7174-7180. PubMed ID: 29126807
[TBL] [Abstract][Full Text] [Related]
59. Protection of mice against P. aeruginosa infections by large-scale affinity-purified human IgG specific to P. aeruginosa outer membrane proteins.
Lee NG; Jung SB; Ahn BY; Kim YG; Lee Y; Jeon YJ; Park WJ
Vaccine; 1999 Nov; 18(7-8):665-74. PubMed ID: 10547426
[TBL] [Abstract][Full Text] [Related]
60. Protection of immunosuppressed mice against translocation of Pseudomonas aeruginosa from the gut by oral immunization with recombinant Pseudomonas aeruginosa outer membrane protein I expressing Salmonella dublin.
Toth A; Schödel F; Duchêne M; Massarrat K; Blum B; Schmitt A; Domdey H; von Specht BU
Vaccine; 1994 Oct; 12(13):1215-21. PubMed ID: 7839727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
